Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study

Cardiovascular Diabetology
Lin ZhuKaty J L Bell

Abstract

The Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Lipid study found no evidence of a beneficial effect of statin-fibrate combined treatment, compared to statins alone, on cardiovascular outcomes and mortality in type 2 diabetes mellitus after 5 years of active treatment. However, a beneficial reduction in major CVD events was shown in a pre-specified sub-group of participants with dyslipidemia. The extended follow-up of this trial provides the opportunity to further investigate possible beneficial effects of fibrates in this group of patients. We aimed to evaluate possible "legacy effects" of fibrate add-on therapy on mortality and major cardiovascular outcomes in patients with dyslipidemia. The ACCORD-lipid study was a randomized controlled trial of 5518 participants assigned to receive simvastatin plus fenofibrate vs simvastatin plus placebo. After randomized treatment allocation had finished at the end of the trial, all surviving participants were invited to attend an extended follow-up study (ACCORDION) to continue prospective collection of clinical outcomes. We undertook a secondary analysis of trial and post-trial data in patients who had dyslipidemia. The primary outcome was all-cause and cardiovascular mort...Continue Reading

References

Nov 30, 2002·Lancet·James ShepherdUNKNOWN PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk
Feb 21, 2009·Nature Clinical Practice. Endocrinology & Metabolism·Arshag D Mooradian
Mar 17, 2010·The New England Journal of Medicine·Henry N GinsbergRobert P Byington
Mar 4, 2011·The New England Journal of Medicine·Hertzel C GersteinWilliam T Friedewald
Jun 17, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Gillian M Keating
Jan 18, 2014·Clinical Chemistry·Mette ThomsenBørge G Nordestgaard
Jan 30, 2014·European Heart Journal·Michael V HolmesJuan P Casas
Dec 29, 2016·JAMA Cardiology·Marshall B ElamUNKNOWN ACCORDION Study Investigators
Oct 6, 2017·Global Cardiology Science & Practice·Mohammed Amin Kashef, Gregory Giugliano
Feb 27, 2019·Current Diabetes Reports·Anastasia-Stefania AlexopoulosJohn R Guyton

❮ Previous
Next ❯

Citations

Aug 28, 2020·Current Rheumatology Reports·Marisa C Mizus, Eleni Tiniakou
Oct 28, 2020·Nutrients·Esther Viñas EsmelEmilio Sacanella Meseguer
Jan 19, 2021·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Jesús Millán Núñez-Cortés, Juan Pedro-Botet
Oct 21, 2020·Advanced Drug Delivery Reviews·Sumra NazirEmiel P C van der Vorst
Apr 26, 2021·Diabetes Research and Clinical Practice·Paul ValensiErwan Donal
May 25, 2021·Metabolism: Clinical and Experimental·Francesco PrattichizzoAntonio Ceriello
Aug 16, 2021·Diabetologia·Rachel Folz, Neda Laiteerapong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.